1 January – 30 June (unaudited)
|
kEUR |
H1 2025 |
H1 2024 |
|
|
|
|
|
|
|
Revenue |
167,096 |
135,043 |
|
|
Other operating income |
|
503 |
787 |
|
Total income |
|
167,599 |
135,830 |
|
|
|
|
|
|
Cost of sales |
|
-153,308 |
-125,287 |
|
Gross profit / (loss) |
|
14,291 |
10,543 |
|
|
|
|
|
|
Marketing and sales expenses |
|
-2,120 |
-1,922 |
|
Research expenses |
|
-909 |
-451 |
|
General and administrative expenses |
|
-24,985 |
-20,741 |
|
Total operating expenses |
|
-28,014 |
-23,114 |
|
|
|
|
|
|
Operating result (EBIT) |
|
-13,723 |
-12,571 |
|
|
|
|
|
|
Financial income |
|
492 |
8,873 |
|
Financial expenses |
|
-17,823 |
-8,613 |
|
Total financial result |
|
-17,331 |
260 |
|
|
|
|
|
|
Result before income taxes |
|
-31,054 |
-12,311 |
|
|
|
|
|
|
Income tax |
|
4,515 |
925 |
|
Result for the period |
|
-26,539 |
-11,386 |
|
|
|
|
|
|
Attributable to shareholders of PolyPeptide Group AG |
|
-26,539 |
-11,386 |
|
|
|
|
|
|
Earnings per share in EUR, basic |
|
-0.80 |
-0.35 |
|
Earnings per share in EUR, diluted |
|
-0.80 |
-0.35 |